Experience

Strand Life Sciences - HCG

• Wellness and Fitness Services
• 1 - 100 Employee

• Senior Research Scientist /Project lead

  • Mar 2016 - Present



Cancyte Technologies Pvt. Ltd.

• Bengaluru, Karnataka, India

• Senior Scientist

  • Sep 2014 - Present



Moffitt Cancer Center

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Research Scientist-I

  • Sep 2012 - Sep 2014

• Postdoctoral Research scientist

  • Sep 2008 - Aug 2012



University of Illinois College of Medicine at Peoria

• Postdoctoral Research Associate

  • Jul 2004 - Aug 2008

  Demonstrated that tumor invasion and SPARC overexpression are closely associated and involve PI3-K and RhoA GTPase shedding light on potential targets for inhibiting tumor cell infiltration in gliomas, and possibly, other cancers. Showed combined use of inhibitors of MMP9 and inhibitors of plasmin/Plg activation system has a synergistic effect in inhibiting breast cancer growth and progression and has significant clinical implications. Further, the data presented supports the development of therapeutic RNAi strategies targeting plasminogen system and proteases for treatment of breast cancer. Demonstrated downregulating MMP-9 activity augments the effect of radiotherapy by directly or indirectly reducing HIF transcription machinery. Since HIF1α is involved in the pathogenesis of several human diseases (e.g., myocardial and cerebral ischemia, pulmonary hypertension), inhibitor of MMP-9 may have a future therapeutic role as a HIF1α activity inhibitor. Show less



Max Delbrück Center

• Germany
• Research Services
• 500 - 600 Employee

• PhD Student

  • 1999 - 2004



IISc, Bangalore

• Research assistant

  • 1995 - 1999